Blog Category


Apr 2020

Potential treatment for COVID-19 identified by BenevolentAI using artificial intelligence enters randomised clinical trial

BenevolentAI announced that baricitinib is entering clinical testing as a potential COVID-19 treatment. Benevolent identified the drug using its AI drug discovery platform. The trial by Eli Lilly will investigate the drug’s efficacy and safety.
Mar 2020

Future Fifty: joining forces to drive forward positive change

BenevolentAI today announced it has been selected for Tech Nation’s 2020 Future Fifty cohort. Our CEO Joanna Shields reflects on how joining forces with like-minded industry experts can serve as a powerful vehicle for transformation.
Feb 2020

MIT Technology Review names BenevolentAI as a top 10 breakthrough tech

We’re proud to be recognised on this prestigious list for our work in AI-driven chemical design. Our compound design is based upon complex multiparametric optimisations which aim to cut the time and cost of designing a drug.
Feb 2020

BenevolentAI announces scientific collaboration with UC San Diego to investigate Cerebral Cavernous Malformations

BenevolentAI announces a scientific collaboration with UC San Diego to investigate CCM. The joint partnership will focus on developing a therapy for CCM - a highly rare disease that currently has no effective treatment